AtriCure, Inc. announced robust financial results for the fourth quarter of 2025, with worldwide revenue increasing by 13.1% year-over-year to $140.5 million. The company also reported a net income of $1.8 million and a positive adjusted EBITDA of $19.9 million, reflecting strong execution and continued momentum across its business.

AtriCure delivered robust third-quarter performance with worldwide revenue reaching $134.3 million, a 15.8% increase year-over-year. The company significantly improved its net loss to $0.3 million and saw a substantial rise in Adjusted EBITDA to $17.8 million, demonstrating strong execution and increasing profitability.

AtriCure delivered stellar second quarter 2025 results with worldwide revenue of $136.1 million, a 17.1% increase year-over-year. The company significantly improved its net loss and saw a substantial increase in Adjusted EBITDA, reflecting strong adoption of its products and therapies globally.

AtriCure reported strong first quarter 2025 results with worldwide revenue increasing 13.6% year over year to $123.6 million. The company significantly improved its net loss, reducing it by $6.5 million year over year, and saw a substantial increase in Adjusted EBITDA, growing by $6.0 million year over year to $8.8 million.

AtriCure, Inc. announced a 16.6% increase in worldwide revenue for the fourth quarter of 2024, reaching $124.3 million. The company reported a net loss of $15.6 million, or $0.33 per share, for the quarter, and positive adjusted EBITDA of $12.7 million.

AtriCure reported strong third-quarter results, with worldwide revenue increasing by 17.9% year-over-year to $115.9 million. The company experienced growth across key product lines and geographies, driven by the adoption of its products and the launch of new products. AtriCure also generated positive cash flow and improved profitability.

AtriCure reported a 15.2% year-over-year increase in worldwide revenue, reaching $116.3 million in Q2 2024. The company also generated $8.1 million in positive cash flow during the quarter. Growth was driven by U.S. pain management, international franchises, and U.S. open appendage management.

AtriCure reported a strong start to 2024, with worldwide revenue increasing by 16.4% year-over-year. U.S. revenue grew by 15.4%, driven by key product lines. International revenue increased by 21.5%.

AtriCure reported a 21.0% increase in worldwide revenue for Q4 2023, reaching $106.5 million. The company experienced growth in both U.S. and International markets. However, the loss from operations increased to $8.7 million, and the adjusted EBITDA was $4.8 million, slightly lower than the previous year.

AtriCure reported a strong third quarter with worldwide revenue increasing by 18.1% year-over-year to $98.3 million. The company experienced growth in both U.S. and international markets, driven by adoption of their products. They also reported a net loss of $9.1 million, an improvement from the previous year, and a positive adjusted EBITDA of $4.7 million.

AtriCure reported strong second-quarter results with a 19.4% increase in worldwide revenue year-over-year. The company's net loss improved significantly, and it achieved positive adjusted EBITDA.

AtriCure reported a strong first quarter in 2023, with a 25.4% increase in worldwide revenue year-over-year, driven by growth in both U.S. and international markets. The company also saw a significant improvement in net loss and achieved positive adjusted EBITDA.

AtriCure reported a revenue of $88.0 million for the fourth quarter of 2022, representing a 20.2% increase compared to the fourth quarter of 2021. The company's loss from operations decreased to $4.1 million, and the net loss per share was $0.09.

AtriCure reported a strong third quarter with revenue of $83.2 million, representing an 18.1% increase year-over-year. U.S. revenue grew by 21.3%, driven by key product lines including cryoSPHERE®, AtriClip® Flex·V®, and ENCOMPASS®. The company experienced a loss from operations of $10.7 million, compared to income of $98.7 million in Q3 2021, which included a significant credit from the change in fair value of contingent consideration.

AtriCure reported a strong second quarter with revenue of $84.5 million, an 18.4% increase year-over-year. The company's U.S. revenue grew by 18.6%, driven by key product lines, while international revenue increased by 17.3%, reflecting a rebound in procedure volumes in Europe and growth in Australia. The company is changing the standard of care for millions of patients globally.

AtriCure reported strong first quarter 2022 financial results, with revenue reaching $74.6 million, a 25.8% increase year-over-year. U.S. revenue grew by 23.8%, driven by cryoSPHERE® probe and AtriClip® Flex-V devices. The company's net loss per share was $0.33.

AtriCure reported a 26.8% increase in revenue for Q4 2021, reaching $73.2 million. The U.S. revenue grew by 29.1% to $61.2 million, driven by strong growth across all product lines. The company's loss from operations was $12.5 million, and the net loss per share was $0.30.

AtriCure reported strong third-quarter results, driven by growth across key product lines and the addition of new Cryo Nerve Block and Hybrid AF™ Therapy accounts. Revenue increased by 28.7% year-over-year, with U.S. and international revenue showing healthy growth. The company is maintaining its full-year revenue guidance.

AtriCure reported a significant increase in revenue for Q2 2021, driven by strong underlying demand and progress in establishing its platforms as standard of care. The company saw revenue growth in both the U.S. and international markets, reflecting the receding impact of the COVID-19 pandemic and increased demand.

AtriCure reported a revenue of $59.3 million for Q1 2021, representing an 11.4% increase compared to Q1 2020. The U.S. revenue increased by 15.7%, while international revenue decreased by 8.1%. The company's net loss per share was $0.38, and the adjusted loss per share was $0.32.

AtriCure's fourth-quarter revenue was $57.7 million, a decrease of 5.9% compared to the fourth quarter of 2019. The decline was driven by the global decline in surgical procedures due to the COVID-19 pandemic. Despite the challenges, the company saw a sequential increase in worldwide revenue of approximately 5% over the third quarter of 2020, reflecting stabilizing procedure volumes.

AtriCure reported a decrease in worldwide revenue by 3.3% year-over-year, with U.S. revenue decreasing by 3.1% and international revenue decreasing by 4.1%. The company's gross profit was $40.3 million, and the loss from operations was $4.0 million. Net loss per share was $0.11, while adjusted EBITDA was a positive $4.2 million.

AtriCure reported a decrease in worldwide revenue by 30.7% year-over-year, with U.S. revenue decreasing by 28.6% and international revenue decreasing by 39.0%. The company experienced a trough in April followed by a rapid return in May and steady volumes through June. They did not provide 2020 financial guidance due to continued uncertainties from the impact of COVID-19.

AtriCure reported a slight decrease in worldwide revenue for Q1 2020, with a more significant decrease in international revenue offsetting growth in the U.S. The company experienced a substantial increase in loss from operations and net loss per share compared to the same period in the previous year.

AtriCure reported a 15.9% increase in revenue for Q4 2019, driven by growth in both U.S. and international markets. The company also highlighted the submission of the final module for the CONVERGE IDE clinical trial and completion of enrollment in the aMAZE IDE clinical trial.